[en] Historically, osteoporosis has been viewed as a disease of women, with research, trials of interventions and guidelines predominantly focused as such. It is apparent, however, that this condition causes a substantial health burden in men also, and that its assessment and management must ultimately be addressed across both sexes. In this article, an international multidisciplinary working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases presents GRADE-assessed recommendations for the diagnosis, monitoring and treatment of osteoporosis in men. The recommendations are based on a comprehensive review of the latest research related to diagnostic and screening approaches for osteoporosis and its associated high fracture risk in men, covering disease burden, appropriate interpretation of bone densitometry (including the use of a female reference database for densitometric diagnosis in men) and absolute fracture risk, thresholds for treatment, and interventions that can be used therapeutically and their health economic evaluation. Future work should specifically address the efficacy of anti-osteoporosis medications, including denosumab and bone-forming therapies.
Disciplines :
Public health, health care sciences & services
Author, co-author :
Fuggle, Nicholas R ; MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK
Beaudart, Charlotte ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie générale ; Clinical Pharmacology and Toxicology Research Unit, Faculty of Medicine, NARILIS, University of Namur, Namur, Belgium ; WHO Collaborating Centre for Epidemiology of Musculoskeletal Health and Ageing, Liège, Belgium
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé ; WHO Collaborating Centre for Epidemiology of Musculoskeletal Health and Ageing, Liège, Belgium
Abrahamsen, Bo ; Odense Patient Data Explorative Network, Institute of Clinical Research University of Southern Denmark, Odense, Denmark
Al-Daghri, Nasser ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé ; Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia
Burlet, Nansa ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé ; WHO Collaborating Centre for Epidemiology of Musculoskeletal Health and Ageing, Liège, Belgium ; The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), Liege, Belgium
Chandran, Manju; Osteoporosis and Bone Metabolism Unit, Department of Endocrinology, Singapore General Hospital, DUKE NUS Medical School, Singapore, Singapore
Rosa, Mario M ; Laboratory of Clinical and Therapeutical Pharmacology, University of Lisbon, Lisbon, Portugal
Cortet, Bernard; Department of Rheumatology, University of Lille, Lille, France
Demonceau, Céline ; Université de Liège - ULiège > Unité de recherche Santé publique, épidémiologie et économie de la santé (URSAPES) ; WHO Collaborating Centre for Epidemiology of Musculoskeletal Health and Ageing, Liège, Belgium
Dere, Willard; Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
Halbout, Philippe; The International Osteoporosis Foundation (IOF), Nyon, Switzerland
Hiligsmann, Mickaël ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé ; Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands
Kanis, John A; Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK ; Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia
Kaufman, Jean-Marc ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé ; Department of Endocrinology, Ghent University Hospital, Ghent, Belgium
Kurth, Andreas; Department of Orthopaedic and Trauma Surgery, Community Clinics Middle Rhine, Campus Kemperhof, Koblenz, Germany
Lamy, Olivier; Centre interdisciplinaire des maladies osseuses, Département de l'appareil locomoteur, Centre hospitalier universitaire vaudois, Lausanne, Switzerland
Laslop, Andrea ; Scientific Office, Federal Office for Safety in Health Care, Vienna, Austria
Matijevic, Radmila; University of Novi Sad, Faculty of Medicine, Clinic for Orthopedic Surgery and Traumatology, Clinical Center of Vojvodina, Novi Sad, Serbia
McCloskey, Eugene ; Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK
Mobasheri, Ali ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé ; Research Unit of Medical Imaging, Physics, and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland
Prieto Yerro, Maria C; Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain
Radermecker, Régis ; Université de Liège - ULiège > Département des sciences cliniques > Pharmacologie clinique
Sabico, Shaun ; Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia
Al-Saleh, Yousef; Odense Patient Data Explorative Network, Institute of Clinical Research University of Southern Denmark, Odense, Denmark ; Department of Endocrinology, Dr. Mohammad Alfagih Hospital, Riyadh, Saudi Arabia
Silverman, Stuart; Department of Medicine, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA
Veronese, Nicola ; Department of Internal Medicine, Geriatrics Section, University of Palermo, Palermo, Italy
Rizzoli, René ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé ; Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
Cooper, Cyrus ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé ; MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK ; NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK ; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique ; WHO Collaborating Centre for Epidemiology of Musculoskeletal Health and Ageing, Liège, Belgium ; Protein Research Chair, Biochemistry Department, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia
Harvey, Nicholas C ; MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK. nch@mrc.soton.ac.uk ; NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK. nch@mrc.soton.ac.uk
E.M. Curtis et al. Epidemiology of fractures in the United Kingdom 1988-2012: Variation with age, sex, geography, ethnicity and socioeconomic status Bone 2016 87 19 26 26968752 4890652 10.1016/j.bone.2016.03.006
J.A. Kanis L.J. Melton III C. Christiansen C.C. Johnston N. Khaltaev The diagnosis of osteoporosis J. Bone Min. Res. 1994 9 1137 1141 1:STN:280:DyaK2M%2FmslSisA%3D%3D 10.1002/jbmr.5650090802
E.S. Orwoll M. Bliziotes Heterogeneity in osteoporosis. Men versus women Rheum. Dis. Clin. North. Am. 1994 20 671 689 1:STN:280:DyaK2M%2Fns1SgsA%3D%3D 7984784 10.1016/S0889-857X(21)00355-0
Rinonapoli, G. et al. Osteoporosis in men: a review of an underestimated bone condition. Int. J. Mol. Sci. 22, https://doi.org/10.3390/ijms22042105 (2021).
J.A. Kanis et al. Long-term risk of osteoporotic fracture in Malmö Osteoporos. Int. 2000 11 669 674 1:STN:280:DC%2BD3M%2FlsFarsw%3D%3D 11095169 10.1007/s001980070064
L.J. Melton III E.J. Atkinson M.K. O’Connor W.M. O’Fallon B.L. Riggs Bone density and fracture risk in men J. Bone Min. Res. 1998 13 1915 1923 10.1359/jbmr.1998.13.12.1915
B. Gullberg O. Johnell J.A. Kanis World-wide projections for hip fracture Osteoporos. Int. 1997 7 407 413 1:STN:280:DyaK1c%2Fos1Kgtg%3D%3D 9425497 10.1007/PL00004148
P.N. Kannegaard S. van der Mark P. Eiken B. Abrahamsen Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival Age Ageing 2010 39 203 209 20075035 10.1093/ageing/afp221
F. Borgström et al. Fragility fractures in Europe: burden, management and opportunities Arch. Osteoporos. 2020 15 32306163 7166207 10.1007/s11657-020-0706-y
K.P. Chang J.R. Center T.V. Nguyen J.A. Eisman Incidence of hip and other osteoporotic fractures in elderly men and women: Dubbo osteoporosis epidemiology study J. Bone Min. Res. 2004 19 532 536 10.1359/JBMR.040109
E. Hernlund et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) Arch. Osteoporos. 2013 8 1:STN:280:DC%2BC2c%2FnsFamsA%3D%3D 24113837 3880487 10.1007/s11657-013-0136-1
L.E. Wehren et al. Gender differences in mortality after hip fracture: the role of infection J. Bone Min. Res. 2003 18 2231 2237 10.1359/jbmr.2003.18.12.2231
H.X. Jiang et al. Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures J. Bone Min. Res. 2005 20 494 500 1:CAS:528:DC%2BD28XmsVSqtQ%3D%3D 10.1359/JBMR.041133
M. Katsoulis et al. Excess mortality after hip fracture in elderly persons from Europe and the USA: the CHANCES project J. Intern. Med. 2017 281 300 310 1:STN:280:DC%2BC1c7mtlyisQ%3D%3D 28093824 10.1111/joim.12586
V.V. Shanbhogue K. Brixen S. Hansen Age- and sex-related changes in bone microarchitecture and estimated strength: a three-year prospective study using HRpQCT J. Bone Min. Res. 2016 31 1541 1549 10.1002/jbmr.2817
P. Wagner R. Chapurlat R. Ecochard P. Szulc Low muscle strength and mass is associated with the accelerated decline of bone microarchitecture at the distal radius in older men: the prospective STRAMBO study J. Bone Min. Res. 2018 33 1630 1640 10.1002/jbmr.3456
E. Seeman The growth and age-related origins of bone fragility in men Calcif. Tissue Int. 2004 75 100 109 1:CAS:528:DC%2BD2cXnsFWlsrg%3D 15383923 10.1007/s00223-004-0289-4
E. Seeman et al. Osteoporosis in men–consensus is premature Calcif. Tissue Int. 2004 75 120 122 1:CAS:528:DC%2BD2cXnsFWlsrc%3D 15185060 10.1007/s00223-004-4002-4
A. Chaitou et al. Association between bone turnover rate and bone microarchitecture in men: the STRAMBO study J. Bone Min. Res. 2010 25 2313 2323 10.1002/jbmr.124
N.B. Watts et al. Osteoporosis in men: an Endocrine Society clinical practice guideline J. Clin. Endocrinol. Metab. 2012 97 1802 1822 1:CAS:528:DC%2BC38Xos1ejtLo%3D 22675062 10.1210/jc.2011-3045
B. Bouvard et al. Recommandations françaises de la prise en charge et du traitement de l’ostéoporose masculine Rev. du Rhum. 2021 88 173 182 10.1016/j.rhum.2021.02.024
Danish Endocrine Society. Treatment of male osteoporosis. https://endocrinology.dk/nbv/calcium-og-knoglemetabolisme/behandling-af-mandlig-osteoporose/ (2022).
C.L. Gregson et al. UK clinical guideline for the prevention and treatment of osteoporosis Arch. Osteoporos. 2022 17 35378630 8979902 10.1007/s11657-022-01061-5
Swedish Osteoporosis Society. Guideline. http://svos.se (2021).
Italian Medicines Agency. Osteoporosis Guideline. http://Aifa.gov.it (2016).
G.H. Guyatt et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations Br. Med. J. 2008 336 924 926 10.1136/bmj.39489.470347.AD
C. Beaudart et al. Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis Aging Clin. Exp. Res. 2023 35 1789 1806 37400668 10460304 10.1007/s40520-023-02478-9
G. Honvo et al. Recommendations for the reporting of harms in manuscripts on clinical trials assessing osteoarthritis drugs: a consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) Drugs Aging 2019 36 145 159 31073927 6509216 10.1007/s40266-019-00667-8
World Health Organization Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. (1994).
J.A. Kanis et al. Towards a diagnostic and therapeutic consensus in male osteoporosis Osteoporos. Int. 2011 22 2789 2798 1:STN:280:DC%2BC3MfosVKruw%3D%3D 21509585 3555694 10.1007/s00198-011-1632-z
C.E. De Laet et al. Hip fracture prediction in elderly men and women: validation in the Rotterdam study J. Bone Min. Res. 1998 13 1587 1593 10.1359/jbmr.1998.13.10.1587
N. Binkley R. Adler J.P. Bilezikian Osteoporosis diagnosis in men: the T-score controversy revisited Curr. Osteoporos. Rep. 2014 12 403 409 25255867 4275049 10.1007/s11914-014-0242-z
J.A. Kanis et al. The need to distinguish intervention thresholds and diagnostic thresholds in the management of osteoporosis Osteoporos. Int. 2023 34 1 9 36282342 10.1007/s00198-022-06567-9
J.A. Kanis et al. A systematic review of hip fracture incidence and probability of fracture worldwide Osteoporos. Int. 2012 23 2239 2256 1:STN:280:DC%2BC38vmvVCksw%3D%3D 22419370 3421108 10.1007/s00198-012-1964-3
J.A. Kanis et al. SCOPE 2021: a new scorecard for osteoporosis in Europe Arch. Osteoporos. 2021 16 82 82 34080059 8172408 10.1007/s11657-020-00871-9
J.A. Kanis et al. A decade of FRAX: how has it changed the management of osteoporosis? Aging Clin. Exp. Res. 2020 32 187 196 32043227 10.1007/s40520-019-01432-y
J.A. Kanis et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women Osteoporos. Int. 2007 18 1033 1046 1:STN:280:DC%2BD2sznvV2hug%3D%3D 17323110 10.1007/s00198-007-0343-y
N.C. Harvey et al. Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice Bone 2015 78 216 224 1:STN:280:DC%2BC2MfltFKksw%3D%3D 25988660 4538791 10.1016/j.bone.2015.05.016
E.V. McCloskey et al. A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX J. Bone Min. Res. 2016 31 940 948 10.1002/jbmr.2734
J.A. Kanis C. Cooper R. Rizzoli J.Y. Reginster European guidance for the diagnosis and management of osteoporosis in postmenopausal women Osteoporos. Int. 2019 30 3 44 1:STN:280:DC%2BB3czps1KrsQ%3D%3D 30324412 10.1007/s00198-018-4704-5
D.L. Kendler et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial Lancet 2018 391 230 240 1:CAS:528:DC%2BC2sXhsl2lur7O 29129436 10.1016/S0140-6736(17)32137-2
K.G. Saag et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis N. Engl. J. Med. 2017 377 1417 1427 1:CAS:528:DC%2BC2sXhslWiurvP 28892457 10.1056/NEJMoa1708322
J.A. Kanis et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures Osteoporos. Int. 2019 31 1 12 31720707 7018677 10.1007/s00198-019-05176-3
E.M. Curtis et al. Management of patients at very high risk of osteoporotic fractures through sequential treatments Aging Clin. Exp. Res. 2022 34 695 714 35332506 9076733 10.1007/s40520-022-02100-4
P. Barrionuevo et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis J. Clin. Endocrinol. Metab. 2019 104 1623 1630 30907957 10.1210/jc.2019-00192
A. Díez-Pérez et al. Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis Bone 2019 120 1 8 30268814 10.1016/j.bone.2018.09.020
M. Lorentzon et al. Algorithm for the use of biochemical markers of bone turnover in the diagnosis, assessment and follow-up of treatment for osteoporosis Adv. Ther. 2019 36 2811 2824 31440982 6822833 10.1007/s12325-019-01063-9
J.A. Kanis et al. An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines: a report for the National Osteoporosis Guideline Group (NOGG) Osteoporos. Int. 2021 32 1951 1960 1:STN:280:DC%2BB3sfmvFWjtQ%3D%3D 33813622 10.1007/s00198-021-05942-2
E. McCloskey et al. FRAX-based assessment and intervention thresholds–an exploration of thresholds in women aged 50 years and older in the UK Osteoporos. Int. 2015 26 2091 2099 1:STN:280:DC%2BC2MbjslejtQ%3D%3D 26077380 10.1007/s00198-015-3176-0
H. Johansson et al. Imminent risk of fracture after fracture Osteoporos. Int. 2017 28 775 780 1:STN:280:DC%2BC1c%2FpvVGquw%3D%3D 28028554 10.1007/s00198-016-3868-0
O. Johnell et al. Fracture risk following an osteoporotic fracture Osteoporos. Int. 2004 15 175 179 1:STN:280:DC%2BD2c7hsVGmug%3D%3D 14691617 10.1007/s00198-003-1514-0
L.A. Ahmed et al. Progressively increasing fracture risk with advancing age after initial incident fragility fracture: the Tromsø study J. Bone Miner. Res. 2013 28 2214 2221 23572401 10.1002/jbmr.1952
T.A. van Geel S. van Helden P.P. Geusens B. Winkens G.J. Dinant Clinical subsequent fractures cluster in time after first fractures Ann. Rheum. Dis. 2009 68 99 102 18677009 10.1136/ard.2008.092775
E.V. McCloskey et al. Short time horizons for fracture prediction tools: time for a rethink Osteoporos. Int. 2021 32 1019 1025 1:STN:280:DC%2BB3sbmvFaqsQ%3D%3D 33914103 7611752 10.1007/s00198-021-05962-y
J.A. Kanis et al. Characteristics of recurrent fractures Osteoporos. Int. 2018 29 1747 1757 1:STN:280:DC%2BB3c%2FitlaltQ%3D%3D 29947869 6076437 10.1007/s00198-018-4502-0
J.A. Kanis et al. Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures Osteoporos. Int. 2020 31 1817 1828 1:STN:280:DC%2BB38nntlOmtw%3D%3D 32613411 7116089 10.1007/s00198-020-05517-7
M. Schini et al. An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis J. Endocrinol. Invest. 2024 47 501 511 1:STN:280:DC%2BB2sbitFSqtg%3D%3D 37874461 10.1007/s40618-023-02219-9
E. Shevroja et al. Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) under the auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging Osteoporos. Int. 2023 34 1501 1529 37393412 10427549 10.1007/s00198-023-06817-4
A. Diez-Perez et al. International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates Osteoporos. Int. 2017 28 767 774 1:CAS:528:DC%2BC2sXhtVKksrY%3D 28093634 5302161 10.1007/s00198-017-3906-6
E.A. Marques et al. Association of bone turnover markers with volumetric bone loss, periosteal apposition, and fracture risk in older men and women: the AGES-Reykjavik longitudinal study Osteoporos. Int. 2016 27 3485 3494 1:STN:280:DC%2BC2s7js1yksQ%3D%3D 27341810 5560053 10.1007/s00198-016-3675-7
G. Corona et al. Testosterone supplementation and bone parameters: a systematic review and meta-analysis study J. Endocrinol. Invest. 2022 45 911 926 1:CAS:528:DC%2BB38XhtFGhurjN 35041193 10.1007/s40618-021-01702-5
J.M. Kaufman Diagnosis of hypogonadism in ageing men Rev. Endocr. Metab. Disord. 2022 23 1139 1150 1:CAS:528:DC%2BB38XivVGltLnI 36355322 10.1007/s11154-022-09763-4
T. Kehoe E. Blind H. Janssen Regulatory aspects of the development of drugs for metabolic bone diseases — FDA and EMA perspective Br. J. Clin. Pharmacol. 2019 85 1208 1212 30335197 10.1111/bcp.13791
D.M. Black et al. Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials Lancet Diabetes Endocrinol. 2020 8 672 682 1:CAS:528:DC%2BB3cXhsVKktr7M 32707115 10.1016/S2213-8587(20)30159-5
R. Eastell et al. Validation of the surrogate threshold effect for change in bone mineral density as a surrogate endpoint for fracture outcomes: the FNIH-ASBMR SABRE project J. Bone Min. Res. 2022 37 29 35 1:CAS:528:DC%2BB3MXis1Ors7nN 10.1002/jbmr.4433
J.S. Hwang et al. The effects of weekly alendronate therapy in Taiwanese males with osteoporosis J. Bone Min. Metab. 2010 28 328 333 1:CAS:528:DC%2BC3cXlvVejtLY%3D 10.1007/s00774-009-0136-9
S. Gonnelli et al. Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study Calcif. Tissue Int. 2003 73 133 139 1:CAS:528:DC%2BD3sXntVWlurg%3D 14565594 10.1007/s00223-002-1085-7
S. Boonen et al. Once-yearly zoledronic acid in older men compared with women with recent hip fracture J. Am. Geriatr. Soc. 2011 59 2084 2090 22091563 10.1111/j.1532-5415.2011.03666.x
S. Boonen et al. Fracture risk and zoledronic acid therapy in men with osteoporosis N. Engl. J. Med. 2012 367 1714 1723 1:CAS:528:DC%2BC38Xhs1eksLrL 23113482 10.1056/NEJMoa1204061
E.S. Orwoll et al. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study J. Bone Min. Res. 2010 25 2239 2250 1:CAS:528:DC%2BC3cXhtlaktbrN 10.1002/jbmr.119
E.S. Orwoll et al. Efficacy and safety of monthly ibandronate in men with low bone density Bone 2010 46 970 976 1:CAS:528:DC%2BC3cXjs1akt70%3D 20060082 10.1016/j.bone.2009.12.034
E. Orwoll et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density J. Clin. Endocrinol. Metab. 2012 97 3161 3169 1:CAS:528:DC%2BC38Xhtlymu7rI 22723310 10.1210/jc.2012-1569
T. Nakamura et al. Clinical trials express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT) J. Clin. Endocrinol. Metab. 2014 99 2599 2607 1:CAS:528:DC%2BC2cXht1WktLbO 24646104 4191553 10.1210/jc.2013-4175
M.A. Fischer et al. Primary medication non-adherence: analysis of 195,930 electronic prescriptions J. Gen. Intern. Med. 2010 25 284 290 20131023 2842539 10.1007/s11606-010-1253-9
V. Rabenda et al. Low incidence of anti-osteoporosis treatment after hip fracture J. Bone Jt. Surg. Am. 2008 90 2142 2148 10.2106/JBJS.G.00864
F. Fatoye P. Smith T. Gebrye G. Yeowell Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review BMJ Open. 2019 9 1:STN:280:DC%2BB3M%2Flslemtg%3D%3D 30987990 6500256 10.1136/bmjopen-2018-027049
M. Hiligsmann et al. Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF) Osteoporos. Int. 2019 30 2155 2165 1:CAS:528:DC%2BC1MXhsFChtrrO 31388696 6811382 10.1007/s00198-019-05104-5
E.S. Orwoll et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis J. Bone Min. Res. 2003 18 9 17 1:CAS:528:DC%2BD3sXltFKmtw%3D%3D 10.1359/jbmr.2003.18.1.9
E.S. Kurland et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers J. Clin. Endocrinol. Metab. 2000 85 3069 3076 1:CAS:528:DC%2BD3cXmsVKrurk%3D 10999788
Qi, Y., Wang, W., Sun, W. L. Pan, Q.-Y. Comparative efficacy and safety of alendronate and teriparatide in bone loss reduction and prevention of vertebral fracture in osteoporotic Chinese patients. Trop. J. Pharm. Res. https://doi.org/10.4314/tjpr.v20i10.26 (2021).
J.S. Finkelstein et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis N. Engl. J. Med. 2003 349 1216 1226 1:CAS:528:DC%2BD3sXns1Kmsrs%3D 14500805 10.1056/NEJMoa035725
M.D. Walker et al. Combination therapy with risedronate and teriparatide in male osteoporosis Endocrine 2013 44 237 246 1:CAS:528:DC%2BC38XhsFKlsr3F 23099796 10.1007/s12020-012-9819-4
E. Czerwinski et al. The efficacy and safety of abaloparatide-SC in men with osteoporosis: a randomized clinical trial J. Bone Min. Res. 2022 37 2435 2442 1:CAS:528:DC%2BB38XislShtb%2FP 10.1002/jbmr.4719
T. Matsumoto et al. Abaloparatide increases lumbar spine and hip BMD in Japanese patients with osteoporosis: the phase 3 ACTIVE-J study J. Clin. Endocrinol. Metab. 2022 107 e4222 e4231 35977548 9516124 10.1210/clinem/dgac486
E.M. Lewiecki et al. A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis J. Clin. Endocrinol. Metab. 2018 103 3183 3193 29931216 10.1210/jc.2017-02163
N.R. Fuggle et al. Assessment of cardiovascular safety of anti-osteoporosis drugs Drugs 2020 80 1537 1552 1:STN:280:DC%2BB38josFSiuw%3D%3D 32725307 7536167 10.1007/s40265-020-01364-2
H.A. Feldman et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study J. Clin. Endocrinol. Metab. 2002 87 589 598 1:CAS:528:DC%2BD38XhsVSjurc%3D 11836290 10.1210/jcem.87.2.8201
J.S. Finkelstein et al. Gonadal steroid-dependent effects on bone turnover and bone mineral density in men J. Clin. Invest. 2016 126 1114 1125 26901812 4767351 10.1172/JCI84137
C. Meier et al. Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study Arch. Intern. Med. 2008 168 47 54 1:CAS:528:DC%2BD1cXhslSntb0%3D 18195195 10.1001/archinternmed.2007.2
J.M. Kaufman Management of osteoporosis in older men Aging Clin. Exp. Res. 2021 33 1439 1452 33821467 10.1007/s40520-021-01845-8
P.J. Snyder et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial JAMA Intern. Med. 2017 177 471 479 28241231 5433755 10.1001/jamainternmed.2016.9539
M. Ng Tang Fui et al. Effect of testosterone treatment on bone microarchitecture and bone mineral density in men: a 2-year RCT J. Clin. Endocrinol. Metab. 2021 106 e3143 e3158 33693907 10.1210/clinem/dgab149
A.M. Lincoff et al. Cardiovascular safety of testosterone-replacement therapy N. Engl. J. Med. 2023 389 107 117 1:CAS:528:DC%2BB3sXhs1Kgt73K 37326322 10.1056/NEJMoa2215025
R. Burge et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 J. Bone Min. Res. 2007 22 465 475 10.1359/jbmr.061113
S.A. Williams et al. Economic burden of osteoporosis-related fractures in the US Medicare population Ann. Pharmacother. 2021 55 821 829 33148010 10.1177/1060028020970518
N. Li et al. Cost effectiveness analyses of interventions for osteoporosis in men: a systematic literature review Pharmacoeconomics 2023 41 363 391 36738425 10020287 10.1007/s40273-022-01239-2
S. Kreck et al. Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model Pharmacoeconomics 2008 26 311 328 18370566 10.2165/00019053-200826040-00004
T.P. van Staa et al. Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids Rheumatology 2007 46 460 466 16899499 10.1093/rheumatology/kel249
J.T. Schousboe et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men J. Am. Med. Assoc. 2007 298 629 637 1:CAS:528:DC%2BD2sXptVWgsLc%3D 10.1001/jama.298.6.629
K. Ito E.B. Elkin M. Girotra M.J. Morris Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer Ann. Intern. Med. 2010 152 621 629 20479027 5468170 10.7326/0003-4819-152-10-201005180-00002
F. Borgström O. Johnell B. Jönsson N. Zethraeus S.S. Sen Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden Bone 2004 34 1064 1071 15193554 10.1016/j.bone.2003.12.028
S. Silverman I. Agodoa M. Kruse A. Parthan E. Orwoll Denosumab for elderly men with osteoporosis: a cost-effectiveness analysis from the US payer perspective J. Osteoporos. 2015 2015 627631 26783494 4689973 10.1155/2015/627631
A. Parthan M. Kruse I. Agodoa S. Silverman E. Orwoll Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective Bone 2014 59 105 113 1:CAS:528:DC%2BC2cXjt12ktg%3D%3D 24231131 10.1016/j.bone.2013.11.002
O. Ethgen M. Hiligsmann N. Burlet J.Y. Reginster Public health impact and cost-effectiveness of dairy products supplemented with vitamin D in prevention of osteoporotic fractures Arch. Public. Health 2015 73 26668740 4677432 10.1186/s13690-015-0099-3
M. Hiligsmann N. Burlet P. Fardellone N. Al-Daghri J.Y. Reginster Public health impact and economic evaluation of vitamin D-fortified dairy products for fracture prevention in France Osteoporos. Int. 2017 28 833 840 1:CAS:528:DC%2BC28XhslSlt7%2FF 27757506 10.1007/s00198-016-3786-1
M. Hiligsmann et al. Cost-effectiveness of vitamin D and calcium supplementation in the treatment of elderly women and men with osteoporosis Eur. J. Public. Health 2015 25 20 25 25096255 10.1093/eurpub/cku119
K. Ito Cost-effectiveness of screening for osteoporosis in older men with a history of falls JAMA Netw. Open 2020 3 33258906 7708999 10.1001/jamanetworkopen.2020.27584
S. Nayak S.L. Greenspan Cost-effectiveness of osteoporosis screening strategies for men J. Bone Min. Res. 2016 31 1189 1199 10.1002/jbmr.2784
M. Schwenkglenks K. Lippuner Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland Osteoporos. Int. 2007 18 1481 1491 1:STN:280:DC%2BD2srosVCktg%3D%3D 17530156 10.1007/s00198-007-0390-4
P. Johansson S. Sadigh P. Tillgren C. Rehnberg Non-pharmaceutical prevention of hip fractures — a cost-effectiveness analysis of a community-based elderly safety promotion program in Sweden Cost Eff. Resour. Alloc. 2008 6 11 18513425 2440733 10.1186/1478-7547-6-11
J. Leal et al. Cost-effectiveness of orthogeriatric and fracture liaison service models of care for hip fracture patients: a population-based study J. Bone Min. Res. 2017 32 203 211 10.1002/jbmr.2995
M. Hiligsmann et al. Cost-effectiveness of sequential abaloparatide/alendronate in men at high risk of fractures in the United States Pharmacoeconomics 2023 41 819 830 37086385 10232643 10.1007/s40273-023-01270-x
R.M. Daly J. Dalla Via R.L. Duckham S.F. Fraser E.W. Helge Exercise for the prevention of osteoporosis in postmenopausal women: an evidence-based guide to the optimal prescription Braz. J. Phys. Ther. 2019 23 170 180 30503353 10.1016/j.bjpt.2018.11.011
R.M. Daly J. Dalla Via J.J. Fyfe R. Nikander S. Kukuljan Effects of exercise frequency and training volume on bone changes following a multi-component exercise intervention in middle aged and older men: secondary analysis of an 18-month randomized controlled trial Bone 2021 148 115944 1:CAS:528:DC%2BB3MXhsVOjtb3K 33836310 10.1016/j.bone.2021.115944
S.E. Lamb et al. Screening and intervention to prevent falls and fractures in older people N. Engl. J. Med. 2020 383 1848 1859 33211928 10.1056/NEJMoa2001500
C. Sherrington et al. Evidence on physical activity and falls prevention for people aged 65+ years: systematic review to inform the WHO guidelines on physical activity and sedentary behaviour Int. J. Behav. Nutr. Phys. Act. 2020 17 33239019 7689963 10.1186/s12966-020-01041-3
R. Rizzoli E. Biver T.C. Brennan-Speranza Nutritional intake and bone health Lancet Diabetes Endocrinol. 2021 9 606 621 1:CAS:528:DC%2BB3MXit1elt7vJ 34242583 10.1016/S2213-8587(21)00119-4
R. Rizzoli et al. Benefits and safety of dietary protein for bone health-an expert consensus paper endorsed by the European Society for Clinical and Economical Aspects of Osteopororosis, Osteoarthritis, and Musculoskeletal Diseases and by the International Osteoporosis Foundation Osteoporos. Int. 2018 29 1933 1948 1:STN:280:DC%2BC1Mfht1Wktw%3D%3D 29740667 10.1007/s00198-018-4534-5
N. Veronese J.Y. Reginster The effects of calorie restriction, intermittent fasting and vegetarian diets on bone health Aging Clin. Exp. Res. 2019 31 753 758 30903600 10.1007/s40520-019-01174-x
C. Beauvais et al. Understanding patients’ perspectives and educational needs by type of osteoporosis in men and women and people with glucocorticosteroid-induced osteoporosis: a qualitative study to improve disease management Calcif. Tissue Int. 2019 105 589 608 1:CAS:528:DC%2BC1MXhslCgurzM 31506706 10.1007/s00223-019-00607-z
Royal Osteoporosis Society. Osteoporosis and men: a message to my younger self. https://theros.org.uk/blog/osteoporosis-and-men-a-message-to-my-younger-self/ (14 June 2022).
Y. Mikyas I. Agodoa N. Yurgin A systematic review of osteoporosis medication adherence and osteoporosis-related fracture costs in men Appl. Health Econ. Health Policy 2014 12 267 277 24477429 10.1007/s40258-013-0078-1
